Fig. 5.
Tumorigenic factors are increased by microbead treatment in the circulation of tumour-bearing mice. (A-F) Quantification of DLL4 (A), FGF7 (B), fractalkine (C), IGFBP10 (D), IL10 (E), and TP (F) in the circulation of vehicle- and microbead-treated mice at day 14 post-LLC injection. Mice received intravenous microbeads at day 1 post-intravenous LLCs. Abbreviations are provided in Table S2. N=4-5/group. *P<0.05, **P<0.01, and ****P<0.0001; unpaired two-tailed Student t-tests. Means±s.e.